min read

Our part in addressing racial inequality

We are committed to positive change and concrete actions that will result in systemic change both within Big Health and in the wider world.

The horrific killing of George Floyd and numerous others, including many Black women, and the outpouring of emotion that followed, has been a shocking wake-up call. These events have highlighted the systemic racism that has, for centuries, perpetuated gross inequities and brutality against Black Americans and people of colour across the world, and has laid bare the divide that continues to exist in our understanding of those injustices.

These experiences have prompted intense reflection across our Big Health team, accompanied by extreme emotion, and many difficult conversations. What has become very clear through all of this is that as a company, we sincerely want to be part of a positive change. We are now committing to concrete actions that will result in systemic change — both within Big Health, and we hope also out in the wider world.

Internally, we need to tackle the systems, processes and organisational culture that perpetuate inequity. The diversity of our team and leadership plays a major role in that. So we are bringing in social impact consultants, The Justice Collective, to shine a light on racist processes or systems within Big Health, and help us build the capabilities we all need to create a truly anti-racist and inclusive work environment.

Externally, our mission to help millions back to good mental health provides us with a powerful opportunity — to directly address the disproportionate impact of healthcare inequity on people of colour, and its role in perpetuating poverty. Our digital therapeutics offer a scalable way to address this gap. Therefore, we will work to ensure our products are accessible, relevant and effective for those impacted by historic and present systemic oppression. And we will actively distribute these products, at no cost, to underserved communities, including people of colour and other groups who experience disparate outcomes, who would otherwise be unable to access our products. We will do so as part of our everyday work, and with the same importance as our paid customers. These commitments will require deep evaluation of our product development and commercial processes, and accountability to these goals from the board level down.

With these areas of focus set, we as Founders take responsibility for delivering lasting change. This can’t be just more “white noise”. It will take time, and we will make mistakes. But together, with ingenuity and tenacity, we are committed to reducing inequity for people of colour — both inside Big Health and in the wider world.

No items found.

Subscribe to blog

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023